𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease

✍ Scribed by Lees, Andrew J.

Book ID
109105736
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
544 KB
Volume
14
Category
Article
ISSN
1080-563X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Employment, medical absenteeism, and dis
Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy
✍ Alexei Korchounov; Gregory Bogomazov 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

## Abstract The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full‐time–employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self‐perception of disability, as well as moto

Evidence-based analysis of physical ther
Evidence-based analysis of physical therapy in Parkinson's disease with recommendations for practice and research
✍ Samyra H.J. Keus; Bastiaan R. Bloem; Erik J.M. Hendriks; Alexandra B. Bredero-Co 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB

## Abstract Physical therapy is often prescribed in Parkinson's disease. To facilitate the uniformity and efficacy of this intervention, we analyzed current evidence and developed practice recommendations. We carried out an evidence‐based literature review. The results were supplemented with clinic

Randomized trial of tolcapone versus per
Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations
✍ William Koller; Andrew Lees; Miroslava Doder; Mariese Hely 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

## Abstract In this 12‐week, randomized, open‐label, blinded‐rater, parallel‐group trial, the efficacy, safety, and tolerability of tolcapone and pergolide were compared in parkinsonian patients with a fluctuating response to levodopa. Patients received tolcapone 100 mg three times daily (t.i.d.),